Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05679_nanopub.RAwMWGelv38MS1ssb0hOCojrx1U12EYzKYLvx4-vL0Bgw#assertion>. }
Showing items 1 to 13 of
13
with 100 items per page.
- drugbank:DB05679 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05679 label "CNTO 1275 [drugbank:DB05679]" assertion.
- drugbank:DB05679 seeAlso DB05679 assertion.
- drugbank:DB05679 description "CNTO 1275 is the experimental name for the human immunosuppressive drug ustekinumab developed by the biotechnology company Centocor. It is a laboratory-manufactured, monoclonal antibody directed against interleukins IL-12 and IL-23 and presently undergoing clinical trials to determine its safety and effectiveness against the diseases Multiple Sclerosis, Psoriasis, and Psoriatic Arthritis." assertion.
- drugbank:DB05679 identifier "drugbank:DB05679" assertion.
- drugbank:DB05679 title "CNTO 1275" assertion.
- drugbank:DB05679 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05679 drugbank_vocabulary:drugbank-id "DB05679" assertion.
- drugbank:DB05679 bio2rdf_vocabulary:x-identifiers.org DB05679 assertion.
- drugbank:DB05679 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05679" assertion.
- drugbank:DB05679 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05679 bio2rdf_vocabulary:identifier "DB05679" assertion.
- drugbank:DB05679 drugbank_vocabulary:x-wikipedia wikipedia:CNTO_1275 assertion.